The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

A dedicated onconephrology service at Brigham and Women’s Hospital has improved kidney outcomes in patients treated for ...

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin approved for add-on severe asthma treatment in 2021 ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

Some Indonesian netizens oppose the clinical trial of a tuberculosis (TB) vaccine candidate in Indonesia, whose development ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...